Pharma Mar (OTCMKTS:PHMMF) Shares Up 4.6% – What’s Next?

Pharma Mar (OTCMKTS:PHMMFGet Free Report) was up 4.6% on Friday . The stock traded as high as $90.21 and last traded at $90.21. Approximately 174 shares changed hands during trading, an increase of 1,844% from the average daily volume of 9 shares. The stock had previously closed at $86.26.

Pharma Mar Stock Up 4.6%

The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.25 and a current ratio of 2.84. The firm has a 50 day moving average price of $87.28 and a 200-day moving average price of $92.78.

Pharma Mar Company Profile

(Get Free Report)

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.

Featured Articles

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.